Top

Selected Publications

Complete PubMed publication record

2021

Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021 Jul 5;218(7). Epub 2021 May 11. PMID: 33974041.
Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, Mancuso JJ, Himmel LE, Lebrun-Vignes B, Wleklinski MJ, Knollmann BC, Srinivasan J, Li Y, Atolagbe OT, Rao X, Zhao Y, Wang J, Ehrlich LIR, Sharma P, Salem JE, Balko JM, Moslehi JJ, Allison JP. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov. 2021 Mar;11(3):614-625. PMID: 33257470.

2020

Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 20(2):75-76, 2/2020. e-Pub 1/2020. PMID: 31925406.
Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 12(548), 6/2020. PMID: 32554706.

2019

Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 1/2019. e-Pub 1/2019. PMCID: PMC6358697.
Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe'er D, Allison JP. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity 50(4):1084-1098.e10, 4/2019. e-Pub 3/2019. PMCID: PMC6664799.
Sharma N, Vacher J, Allison JP. TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. Proc Natl Acad Sci U S A 116(21):10453-10462, 5/2019. e-Pub 5/2019. PMCID: PMC6534983.
Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res. e-Pub 7/2019. PMID: 31289040.
Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A 116(44):22246-22251, 10/2019. e-Pub 10/2019. PMID: 31611368.
Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. e-Pub 10/2019. PMID: 31636208.
Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. e-Pub 12/2019. PMID: 31873309.

2018

Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res 6(2):189-200, 2/2018. e-Pub 1/2018. PMID: 29339377.

2017

Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 8:14340, 2/2017. e-Pub 2/2017. PMCID: PMC5316835.
Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-53, 4/2017. e-Pub 2/2017. PMCID: PMC5809128.
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-5, 5/2017. e-Pub 3/2017. PMCID: PMC5466900.
Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-33.e17, 9/2017. e-Pub 8/2017. PMCID: PMC5591072.

2011-2016

Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6(4):e19499, 4/2011. e-Pub 4/2011. PMCID: PMC3085474.
Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol 186(9):5039-45, 5/2011. PMID: 21505216.
Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med 208(8):1683-94, 8/2011. e-Pub 7/2011. PMCID: PMC3149222.
Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan-Bonnet G, Allison JP. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A 109(3):881-6, 1/2012. e-Pub 1/2012. PMCID: PMC3271915.
Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, Allison JP. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 72(2):430-9, 1/2012. e-Pub 11/2011. PMCID: PMC4526218.
Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol 188(3):976-80, 2/2012. e-Pub 12/2011. PMID: 22198953.
Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol 189(3):1123-7, 8/2012. e-Pub 7/2012. PMID: 22753941.
Corse E, Gottschalk RA, Park JS, Sepulveda MA, Loke P, Sullivan TJ, Johnson LK, Allison JP. Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. J Immunol 190(2):526-30, 1/2013. e-Pub 12/2012. PMCID: PMC4964790.
Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 210(4):743-55, 4/2013. e-Pub 4/2013. PMCID: PMC3620352.
Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210(7):1389-402, 7/2013. e-Pub 6/2013. PMCID: PMC3698523.
Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1(4):229-34, 10/2013. e-Pub 7/2013. PMCID: PMC4636341.
Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32, 3/2014. PMCID: PMC4106918.
Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 211(4):715-25, 4/2014. e-Pub 3/2014. PMCID: PMC3978270.
Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunol Res 2(10):970-80, 10/2014. e-Pub 7/2014. PMID: 25038199.
Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol 194(5):2089-98, 3/2015. e-Pub 1/2015. PMID: 25624453.
Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G, Savage PA, van den Brink MR, Allison JP. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer Immunol Res 3(8):849-54, 8/2015. e-Pub 6/2015. PMCID: PMC5939565.

Historical Publications

Allison J.P., McIntyre B.W., Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol 129:2293-2300; 1982.
- The first identification of the T cell antigen receptor (TCR).
McIntyre B.W., Allison J.P. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell 34:739-746; 1983.
- The first detailed structure of the T cell antigen receptor protein showing it to be a disulfide-linked heterodimer with constant and variable peptides on both chains.
Harding F.A., McArthur J.G., Gross J.A., Raulet D.H., Allison J.P. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607-609; 1992.
- Identification of CD28 as the T cell receptor for costimulatory signals required, in addition to the TCR, for activation of naïve T cells and prevention of anergy, opening the door to molecular studies of costimulation.
Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465; 1995.
- This paper showed that the CD28 homolog CTLA-4 is not a costimulator, as was generally accepted at the time, but rather acts as an inhibitor of T cell activation, the first known cell intrinsic inhibitory pathway.
Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736; 1996.
- This paper showed that blockade of the inhibitory effects of CTLA-4 in vivo is sufficient to obtain rejection and durable immunity to tumors of diverse histology and proposed the notion of immune checkpoint blockade in cancer therapy. It led to several patents and the clinical development and ultimate FDA approval of ipilimumab for the treatment of both metastatic and adjuvant melanoma. This led to acceptance of immunotherapy as a pillar of cancer treatment and the new paradigms of immune checkpoint blockade and immune-oncology.
van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366; 1999.
- Showed that combination of CTLA-4 blockade and a genetically modified tumor cell vaccine were synergistic in treatment of a poorly immunogenic tumor.
Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206: 1717-1725; 2009.
- This paper largely resolved a controversy regarding the cellular targets and mechanism of action of anti-CTLA-4 by showing that targeting only regulatory CD4 T cells had no anti-tumor effects, but targeting effector CD4 T cells provided anti-tumor responses, which were further enhanced with the addition of blockade of CTLA-4 on regulatory T cells.
Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T-cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107:4275-4280; 2010.
- This preclinical study showed that a combination of anti-CTLA-4 and antibodies to a second immune checkpoint, PD-1, were additive, presaging a clinical study reported in 2013 showing a 50% response rate in metastatic melanoma and subsequent FDA approval of this combination in the treatment of metastatic melanoma.
Fan X., Quezada S.A., Sepulveda M.A., Sharma P., Allison J.P. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 211:715-725; 2014.
- This pre-clinical study showed that agonistic stimulation of ICOS, a costimulatory receptor on the surface T cells expressed after anti-CTA-4 treatment, could greatly enhance the efficacy of CTLA-4 blockade, a finding that has led to a patent and the clinical development of agonistic ICOS antibody by several pharmaceutical companies
Zamarin D., Holmgaard R.B., Subudhi S.K., Park J.S., Mansour M., Palese P., Merghoub T., Wolchok J.D., Allison, J.P. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6:226ra32; 2014.
- This paper showed that local delivery of the oncolytic Newcastle Disease Virus, together with intraperitoneal delivery of anti-CTLA-4, resulted in rejection of distant tumors, leading to a patent which has been licensed to a pharmaceutical company for clinical development.
Wei S.C., Levine J.H., Cogdill A.P., Zhao Y., Anang N.A.S., Andrews M.C., Sharma P., Wang J., Wargo J.A., Pe'er D., Allison J.P. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 170(6):1120-1133; 2017.
- This paper identified more than 15 tumor-infiltrating T cell populations and determined that anti-CTLA-4 and anti-PD-1 utilize distinct cellular mechanisms, suggesting the possibility of combinatorial treatments.

Selected Publications

2021

2020

2019

2018

2017

2011-2016

Historical Publications

Give Now

Research Areas

Subscribe